Mass Tort brief
UK Consumer Claims and US Product Liability Litigation
A landmark English court ruling eases the path for mass consumer claims, while revived US paracetamol lawsuits threaten UK pharmaceutical giants.
Mass Tort
The Court of Appeal has cleared the path for low-cost litigation aggregation — making it far cheaper for claimant firms to target UK financial institutions with massive consumer lawsuits.
BackgroundUnder English civil procedure, claims must typically be filed individually unless they are consolidated via a formal Group Litigation Order. Lenders had argued that individualized consumer complaints could not be tried together, attempting to force claimants to fund thousands of separate cases.
- The judges ruled that trying representative lead cases provides a proportionate way to resolve common issues, preventing lenders from dragging out individual disputes to exhaust claimant funds.
- Bypassing the expensive hurdles of formal Group Litigation Orders will slash upfront legal costs, allowing litigation-funded firms to profitably aggregate thousands of low-value consumer actions.
- The ruling directly exposes major UK lenders like Lloyds Banking Group and Close Brothers to escalating liabilities, as claimant law firms prepare to launch similar omnibus filings.
Mass Tort
The revival of US paracetamol autism lawsuits has renewed legal risks for GSK and Haleon — exposing the UK consumer giants to massive liabilities if the cases reach juries.
BackgroundMultidistrict litigations (MDLs) consolidate thousands of individual US lawsuits before a single federal judge to streamline pretrial proceedings. Under American law, judges act as strict scientific gatekeepers to ensure expert testimony is reliable before allowing cases to proceed to juries.
- The Second Circuit Court of Appeals reversed a lower court ruling that excluded the plaintiffs' medical experts, forcing the trial judge to re-evaluate evidence linking prenatal paracetamol use to autism.
- Pharma defense lawyers warned the ruling weakens strict scientific gatekeeping standards, potentially allowing experts to present unproven, fringe medical theories directly to sympathetic juries.
- The litigation is being watched by the UK's Medicines and Healthcare products Regulatory Agency, as any US shift in safety liability could force new packaging warnings for British consumers.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.